Patents by Inventor John Musser

John Musser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9167804
    Abstract: Embodiments disclosed herein disclose a fish brooding and filtration system. The system includes a brooding tank configured to contain water and fish for breeding. The brooding tank is in fluid communication a filtration tank, which is configured to extract nitrites from the water circulating through the system. A pump circulates the water through at least one conduit and an injector that receives a flow of water generated by the pump and draws air into the injector. The injector is further operable to inject a mixture of the drawn air and the water into the brooding tank.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: October 27, 2015
    Inventor: John Musser
  • Publication number: 20150037878
    Abstract: Embodiments disclosed herein disclose a system for brewing compost tea. The system includes a bucket that has an opening and a handle. A lid defining a plurality of holes and is configured to cover the opening in the bucket. An air pump is coupled to the lid. At least one air hose is coupled to the air pump and received through one of the holes. At least one air stone is coupled to the at least one air hose. The air pump is operable to cause air bubbles to be expelled from the at least one air stone to facilitate aeration of a compost tea mixture contained by the bucket.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventor: John Musser
  • Publication number: 20130319342
    Abstract: Embodiments disclosed herein disclose a fish brooding and filtration system. The system includes a brooding tank configured to contain water and fish for breeding. The brooding tank is in fluid communication a filtration tank, which is configured to extract nitrites from the water circulating through the system. A pump circulates the water through at least one conduit and an injector that receives a flow of water generated by the pump and draws air into the injector. The injector is further operable to inject a mixture of the drawn air and the water into the brooding tank.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 5, 2013
    Inventor: John Musser
  • Publication number: 20080090785
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: May 9, 2005
    Publication date: April 17, 2008
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, Kevin Shenk, Peggy Radel
  • Publication number: 20070282114
    Abstract: Methods for extraction, isolation, and purification of therapeutically useful compounds from Tripterygium wilfordii are described. Extraction steps employing aqueous base and a hydrocarbon solvent, respectively, are found to increase the efficiency of the process and reduce the amount of material that must be removed by chromatography.
    Type: Application
    Filed: February 7, 2005
    Publication date: December 6, 2007
    Inventors: Jinhua An, Rensheng Xu, John Musser
  • Publication number: 20070249048
    Abstract: Compounds useful as immunosuppressive, anti-inflammatory and anticancer agents and methods of their preparation and use are described. The compounds are analogs or derivatives of triptolide and related compounds, modified at the 5- and/or 6-position relative to the naturally occurring compounds.
    Type: Application
    Filed: December 20, 2004
    Publication date: October 25, 2007
    Inventors: Dongcheng Dai, John Musser, Hongwei Yuan
  • Publication number: 20070244080
    Abstract: Inflammatory disorders, including obliterative airway disease, renal fibrosis, diabetic nephropathy, and liver fibrosis are treated with immunosuppressive triptolide compounds, in particular triptolide compounds effective to inhibit TGF-? production in a patient afflicted with such a disorder.
    Type: Application
    Filed: June 23, 2005
    Publication date: October 18, 2007
    Applicant: PHARMAGENESIS, INC.
    Inventors: John Fidler, John Musser
  • Publication number: 20070191284
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 11, 2007
    Publication date: August 16, 2007
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser
  • Publication number: 20060128975
    Abstract: Compounds having the structure I: are useful for inducing cell death (apoptosis) and in immunosuppression. In structure I, R1 is H or R, R being selected from lower alkyl, alkenyl, alkynyl, and allenyl, or, R1 together with R2=O (oxo); R2=OH, or, R1 and R2 together=O (oxo); CR3R5 and CR4R6 are selected from CH2, CHOH and CROH; at least one of R1, R5 and R6 is R; and at least one of CR3R5 and CR4R6 is CH2.
    Type: Application
    Filed: January 27, 2006
    Publication date: June 15, 2006
    Inventors: Dongcheng Dai, John Musser
  • Publication number: 20050288364
    Abstract: Compounds having the structure I: are useful for inducing cell death (apoptosis) and in immunosuppression. In structure I, CR1R2 is selected from CHOH, C?O, CHF, CF2 and C(CF3)OH; CR6 and CR13 are selected from CH, COH and CF; CR7R8, CR9R10 and CR11R12 are selected from CH2, CHOH, C?O, CHF and CF2; and CR3R4R5 is selected from CH3, CH2OH, C?O, COOH, CH2F, CHF2 and CF3; such that: at least one of R1-R13 comprises fluorine; no more than two of CR3R4R5, CR6, CR7R8, CR9R10, CR11R12, and CR13 comprises fluorine or oxygen; and, when CR1R2 is CHOH, CR3R4R5 is not CH2F.
    Type: Application
    Filed: August 23, 2005
    Publication date: December 29, 2005
    Inventors: Dongcheng Dai, John Musser
  • Publication number: 20050245435
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
    Type: Application
    Filed: April 14, 2005
    Publication date: November 3, 2005
    Applicant: Proteolix, Inc.
    Inventors: Mark Smyth, Guy Laidig, Ronald Borchardt, Barry Bunin, Craig Crews, John Musser, John Schneekloth, John Chabala
  • Patent number: 5326752
    Abstract: The compounds are of the formula ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, lower alkyl (1-4C), alkylaryl or one or more additional saccharide residues; R.sup.3 and R.sup.4 are independently H, alkyl (1-6C), aryl or R.sup.3 and R.sup.4, taken together, form a five or six-membered ring optionally containing a hetroatom selected from the group consisting of O, S, and NR.sup.1 ; wherein said five- or six-membered ring may further be substituted by one or more substituents selected from the group consisting of (CHOR.sup.1).sup.m H wherein m is 1-4, OR.sup.1, OOCR.sub.1, NR.sup.1, NCOR.sup.1 and SR.sup.1 ; Y is H, OR.sup.1, OOCR.sup.1, NR.sup.1.sub.2, NCOR.sub.1 or SR.sub.1 ; and X is --CHR.sup.5 (CHOR.sup.1).sub.2 CHR.sup.6 OR.sup.1 wherein R.sup.5 and R.sup.6 are independently H, lower alkyl (1-4C) optionally substituted with one or more R, or result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S and NR.sup.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: July 5, 1994
    Assignee: Glycomed Incorporated
    Inventors: Mina Nashed, Falguni Asgupta, Saeed Abbas, John Musser, Darwin Asa
  • Patent number: 4276292
    Abstract: New triazolobenzoxazinones are described as well as the use thereof as anti-allergenic agents.
    Type: Grant
    Filed: May 12, 1980
    Date of Patent: June 30, 1981
    Assignee: USV Pharmaceutical Corporation
    Inventors: Vasil St. Georgiev, Bernard Loev, Robert Mack, John Musser